Clinical Trial

Topical Phenytoin for Management of Gingival Recession

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Gingival recession (GR) is a term that describes the displacement of the gingival margin apical to the cemento-enamel junction (CEJ) of a tooth. The gold standard of GR treatment is surgical coverage through coronally advanced flap with subepithelial connective tissue graft (CAF+SCTG) (3). But, the need for a non-invasive technique for managing GR has not been frequently addressed. Phenytoin (PHT), used as an anti-seizure medication, has an established side effect of causing drug-influenced gingival enlargement. Its stimulatory effects on soft tissue metabolism suggested PHT to be tested topically for its effectiveness in wound healing. However, none of the previous studies that investigated topical phenytoin has assessed gingival recession; except for a case series.
Trial Details
NCT Number NCT07590375
Lead Sponsor Cairo University
Conditions Gingival Recession
Enrollment 30 participants
Start Date 2026-06-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-15